This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health (OPK) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, OPKO Health (OPK) closed at $4.30, marking a +0.7% move from the previous day.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
OPKO Health (OPK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OPKO Health (OPK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $4.30, moving +1.78% from the previous trading session.
OPKO Health (OPK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $4.40, moving +1.15% from the previous trading session.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.
Implied Volatility Surging for OPKO (OPK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OPKO (OPK) stock based on the movements in the options market lately.
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.18 in the latest trading session, marking a -1.24% move from the prior day.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Has OPKO Health (OPK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Veeva CRM to Help Medis Deliver Customized Experience to HCPs
by Zacks Equity Research
Veeva Systems' (VEEV) CRM will be lending Medis teams a flexible solution that adapts to the unique go-to market strategies of every customer.
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $3.22, moving -0.92% from the previous trading session.
AngioDynamics Unveils Auryon Atherectomy System for PAD
by Zacks Equity Research
AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.
Accuray's Radixact With Synchrony Used in Japan Hospitals
by Zacks Equity Research
The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
by Zacks Equity Research
OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -0.63% move from the prior day.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.
Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?